Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: DNA methylation in bladder cancer

PROVIDER: PRJNA1131921 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29752400_1.fastq.gz	Fastqsanger.gz
	SRR29752400_2.fastq.gz	Fastqsanger.gz
	SRR29752401_1.fastq.gz	Fastqsanger.gz
	SRR29752401_2.fastq.gz	Fastqsanger.gz
	SRR29752402_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 58

Similar Datasets

Genome-wide DNA methylation study in bladder cancer

Project description:Genome-wide DNA methylation profiles were determined on a set of fresh 44 bladder cancer tissues using normal blood as control. DNA amplicons were prepared using Differential Methylation Hybridization (DMH) method, subsequently hybridized on to the Agilent Human CpG island Microarray. The goal was to unravel the DNA methylation patterns in different subgropus of bladder cancer along with finding markers for progresssion and early diagnosis. 44 bladder cancer tissues were profiled against commercially available normal human genomic blood DNA (Promega, Madison, WI, USA) as a reference

2012-02-16 | E-GEOD-35824 | biostudies-arrayexpress

Epigenome analysis of parental (native) and 3-bromopyruvate-resistant UM-UC-3 bladder cancer cells

Project description:Genome-wide DNA methylation profiling of parental (native) and 3-bromopyruvate-resistant UM-UC-3 bladder cancer cells. The Illumina Infinium 450k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 450,000 CpGs in treatment-naive and 3-bromopyruvate-resistant UM-UC-3 bladder cancer cells.

2021-05-04 | GSE173764 | GEO

Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients

Project description:Epigenome-wide association study (EWAS) of blood samples from a case-control study of bladder cancer. The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in peripheral blood. Samples included peripheral blood samples from 223 incident cases of bladder cancer and 205 control subjects. Bisulphite converted DNA from the 428 samples were hybridized to the Illumina Infinium 27k Human Methylation Beadchip v1.2

2013-08-29 | E-GEOD-50409 | biostudies-arrayexpress

Genome-wide DNA methylation study in bladder cancer

2012-02-16 | GSE35824 | GEO

Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients

2013-08-29 | GSE50409 | GEO

Homo sapiens

Project description:DNA methylation and expression profiling study for bladder cancer [methylation]

| PRJNA163667 | ENA

Genome-wide DNA methylation study in bladder cancer

Project description:Genome-wide DNA methylation study in bladder cancer

| PRJNA719302 | ENA

Homo sapiens

Project description:Genome-wide DNA methylation study in bladder cancer

| PRJNA152161 | ENA

Identification of a novel set of DNA methylation markers in bladder cancer using MBD-methylCap/seq and urine DNA screening in a Chinese population

Project description:The aim of the present study was to identify novel DNA methylation markers in bladder cancer (BCa) through genome-wide profiling of bladder cancer cell lines and subsequent MSP screening in urine samples. Experimental Design: MBD methylCap/seq was carried out to screen differentially methylated CpG islands using two BCa cell lines (5637 and T24) and two normal bladder mucosa (BM) samples. The top one hundred most hypermethylated targets were screened using Methylation Specific PCR (MSP) in small and big cohort of urine samples from BCa patients and normal controls. The diagnostic performance of the gene panel was further evaluated in different clinical scenarios. Results: In total, 1,627 gene promoter regions hypermethylated in BCa cell line were identified in genomic level methylation profiling. The followed screening procedure in clinical urine sample generated eight genes (VAX1, KCNV1, ECEL1, TMEM26, TAL1, PROX1, SLC6A20, and LMX1A) capable of differentiating BCa from normal control. Subsequent validation in a large sample size enabled the optimisation of 5 methylation targets (VAX1, KCNV1, TAL1, PPOX1 and CFTR) for BCa diagnosis with sensitivity and specificity of 86.32% and 87.13%, respectively. In addition, VAX1 and LMX1A methylation could predict the tumour recurrence. Conclusions: Tumor specific biomarkers of BCa could be established by first performing genome level methylation profiling with cell lines and then screening the potential targets in urine samples. The panel of methylated genes identified was promising for the early non-invasive detection and surveillance of BCa. MBD methylCap/seq was carried out to screen differentially methylated CpG islands using two BCa cell lines (5637 and T24), and two normal bladder tissue mix as control.

2012-04-30 | E-GEOD-33839 | biostudies-arrayexpress

DNA methylation and expression profiling study for bladder cancer

Project description:DNA methylation and expression profiling study for bladder cancer

| PRJNA163609 | ENA